Related Experiment Video
Updated: Aug 6, 2026
07:26
Isolation of Functional Cardiac Immune Cells
Published on: December 5, 2011
Mast Cell St8sia1 Is a Glyco-Epigenetic Checkpoint Driving Cardiac Remodeling
Changzuan Zhou1, Lisheng Fu1, Tianyou Yuan1
1Department of Cardiology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, China.
Circulation Research
|August 5, 2026
Summary
Targeting the St8sia1-GD3 axis in cardiac mast cells (MCs) can prevent chronic heart failure progression. Inhibiting this glyco-epigenetic pathway improves cardiac function and reduces inflammation.
Area of Science:
- Immunology
- Cardiology
- Glycobiology
Background:
- Chronic heart failure involves immune-cardiac crosstalk, but targeted therapies are lacking.
- Glycoconjugates are vital for cell signaling and extracellular matrix integrity.
- This study investigates glycoconjugate-metabolizing enzymes at the immune-cardiac interface.
Purpose of the Study:
- To define the role of glycoconjugate-metabolizing enzymes in immune-cardiac crosstalk.
- To evaluate the translational potential of targeting these enzymes for heart failure treatment.
Main Methods:
- Integrative analysis of human and mouse heart RNA sequencing data.
- Utilized mouse models of pressure overload and ischemia-reperfusion.
- Employed genetic deletion, bone-marrow chimeras, and pharmacological neutralization.
Main Results:
- St8sia1, a GD3 synthase, was induced in cardiac mast cells (MCs) during heart failure.
- MC-specific deletion of St8sia1 preserved cardiac function and reduced inflammatory cell recruitment.
- Neutralization of GD3 with antibody R24 improved cardiac function and reduced scar formation.
Conclusions:
- The St8sia1-GD3 axis in MCs acts as a glyco-epigenetic checkpoint in cardiac remodeling.
- Targeting this axis offers a translatable immunomodulatory strategy for heart failure.
